γ-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity

Cancer Research

Volumn 69, Issue 2, 2009, Pages 573-582

  Meng, Raymond D ^a   Shelton, Christopher C ^a   Li, Yue Ming ^a   Qin, Li Xuan ^a   Notterman, Daniel ^b   Paty, Philip B ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; GAMMA SECRETASE INHIBITOR; GSI 34; IRINOTECAN; NICASTRIN; NOTCH1 RECEPTOR; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SUBUNIT; SMALL INTERFERING RNA; SULFONAMIDE; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CHEMOSENSITIVITY; COLON CANCER; COLON CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME ACTIVATION; HCT116 CELLS; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 58349091690     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2088     Document Type: Article

References (48)

1. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007;17:52-9.
2. Shih IeM, Wang TL. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82.
3. Katoh M, Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol 2007;30:247-51.
4. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715-24.
5. Nair P, Somasundaram K, Krishna S. Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J Virol 2003;77:7106-12.
6. Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001;20:3427-36.
7. Sade H, Krishna S, Sarin A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004;279:2937-44.
8. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-κb, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
9. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25.
10. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001;21:5925-34.
11. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20:2096-109.
12. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
13. Hopfer O, Zwahlen D, Fey MF, Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 2005;93:709-18.
14. Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated withpro state cancer metastasis and recurrence. Cancer Res 2004;64:6854-7.
15. Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-93.
16. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. γ secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005;24:6333-44.
17. Li Y, Rao PK, Wen R, et al. Notch and Schwann cell transformation. Oncogene 2004;23:1146-52.
18. Farnie G, Clarke RB, Spence K, et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007;99:616-27.
19. Weng AP, Nam Y, Wolfe MS, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003;23:655-64.
20. Akiyoshi T, Nakamura M, Yanai K, et al. γ-Secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 2008;134:131-44.
21. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503-10.
22. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article 3. Epub 2004 Feb 12.
24. Lewis SJ, Smith AL, Neduvelil JG, et al. A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg Med Chem Lett 2005;15:373-8.
25. Li YM, Lai MT, Xu M, et al. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A 2000;97:6138-43.
26. Veenendaal LM, Kranenburg O, Smakman N, Klomp A, Borel Rinkes IH, van Diest PJ. Differential Notch and TGFβ signaling in primary colorectal tumors and their corresponding metastases. Cell Oncol 2008;30:1-11.
27. Stockhausen MT, Sjölund J, Manetopoulos C, Axelson H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 2005;92:751-9.
28. LeFort K, Mandinova A, Ostano P, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinases. Genes Dev 2007;21:562-77.
29. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature 2008;451:76-80.
30. Alimirah F, Panchanathan R, Davis FJ, Chen J, Choubey D. Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia 2007;9:427-34.
31. Takeshita K, Satoh M, Ii M, et al. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 2007;100:70-8.
32. Jin SM, Cho HJ, Jung MW, Mook-Jung I. DNA damage-inducing agent-elicited γ-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades. Cell Death Differ 2007;14:189-92.
33. Seo SJ, Hwang DY, Cho JS, et al. PEN-2 overexpression induces γ-secretase protein and its activity with amyloid β-42 production. Neurochem Res 2007;32:1016-23.
34. Li J, Fici GJ, Mao CA, et al. Positive and negative regulation of the γ-secretase activity by nicastrin in a murine model. J Biol Chem 2003;278:33445-9.
35. Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-53.
36. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007;12:942-51.
37. Kim SB, Chae GW, Lee J, et al. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ 2007;14:982-91.
38. Chen Y, De Marco MA, Graziani I, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 2007;67:7954-9.
39. Hata T, Yamamoto H, Ngan CY, et al. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 2005;4:1585-94.
40. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 2004;3:169-78.
41. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 2006;5:1883-94.
42. Liu ZJ, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 2006;66:4182-90.
43. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110:278-86.
44. Ramdass B, Maliekal TT, Lakshmi S, et al. Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression. Gynecol Oncol 2007;104:352-61.
45. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
46. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203-10.
47. Curry CL, Reed LL, Broude E, Golde TE, Miele L, Foreman KE. Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-κB signaling. Mol Cancer Ther 2007;6:1983-92.
48. Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias [abstract]. ASCO Annual Meet Proc 2006;24:6585.